INTRODUCTION
Insulinlike growth factor (IGF)1-I and IGF-II are closely related polypeptides purified from human plasma that have major amino acid sequence homologies to human proinsulin (1, 2) . Like insulin and other polypeptide hormones, IGF-I and IGF-II initiate their biological actions by being recognized by specific receptors on the surface of responsive target tissues. At least two subtypes of IGF receptors can be distinguished by their relative reactivity with IGF-I and IGF-II and by their ability to interact with insulin (3, 4) . In addition, the IGFs exhibit weak cross-reactivity with insulin receptors, as reflected by inhibition of 1251_ insulin binding in competitive binding experiments (5, 6) .
Recently, we and others have reported that two types of IGF receptor structures can be demonstrated by affinity labeling techniques (7, 8) and that the differences in receptor subunit organization correlated perfectly with the previously observed differences in the specificity of binding (9, 10 of -220,000 before reduction and Mr of -260,000 after reduction, suggesting that they contain internal disulfide bonds, but that they are not linked by disulfide bridges to other membrane proteins. The structure of Type I, but not Type II, IGF receptors is quite similar to that determined for insulin receptors by similar affinity labeling techniques,2 although the two receptors can be distinguished by the relative abilities of insulin and IGF to inhibit the binding of the labeled ligands (9, 10, (12) (13) (14) (15) (16) .
The marked similarity of the Type I IGF receptor and the insulin receptor raised the question whether the IGF-I and insulin binding sites might represent different domains on the same Mr -130,000 protein, or whether they are present on separate but highly homologous structures. To address this question, we used sera from a group of patients with the Type B syndrome of extreme insulin resistance and acanthosis nigricans that are known to possess circulating autoantibodies to insulin receptors (17) . These polyclonal immunoglobulins inhibit insulin binding and immunoprecipitate insulin receptors from a variety of tissues and species (11) . We examined the ability of these autoantibodies, as well as a rabbit antiserum to the insulin receptor, to inhibit binding to and immunoprecipitate Type I IGF receptors.
METHODS
Cell cultivation IM-9 cells, an established line of human lymphoblasts (18) , were obtained from S. Taylor (Diabetes Branch, National Institutes of Health) and R. G. Rosenfeld (Stanford University, Stanford, CA) and propagated in continuous suspension culture at 370C in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% (vol/vol) fetal bovine serum (feheis Chemical Co., Phoenix, AZ).
BRL 3A2 cells, a cloned line of rat liver cells, were grown in monolayer culture in a humidified incubator (37°C, 5% CO2) in modified Ham's F12 medium containing 5% (vol/ vol) fetal bovine serum as previously described (4) . 2 By experimental techniques other than affinity cross-linking, a second subunit of M, 90,000 has also been identified in insulin receptors (11) .
Fao rat hepatoma cells, a clonal line of well-differentiated rat hepatoma cells derived from the Reuber H-35 hepatoma (19) , were maintained in monolayer culture in modified Ham's F12 medium supplemented with 5% fetal bovine serum.
Human placental membranes A crude membrane fraction containing microsomal and plasma membranes (100,000-g pellet) was prepared from normal human fresh-frozen full-term placentae, as described previously (20) .
Summary of receptor preparations used in this study
The distribution of insulin receptors and Type I and Type II IGF receptors on human placental membranes, IM-9 lymphoblasts, Fao hepatoma cells, and BRL 3A2 cells is summarized in Table I .
Peptides
Porcine insulin (lot lJM95AN) was purchased from Elanco Products Co., (Indianapolis, IN). IGF-I (16SPII) purified from human plasma (1) was a generous gift of Rene E. Humbel (Biochemisches Institut der Universitat Zurich, Switzerland). A partially purified preparation (No. 1932) of IGF having a specific insulinlike activity of 36 mU/mg in the fat pad bioassay was used for some experiments where indicated. Multiplication-stimulating activity (MSA) 11-1 (M, 8 ,700) from serum-free culture medium conditioned by the BRL 3A cell line was purified by Dowex chromatography, Sephadex G-75 gel filtration, and preparative electrophoresis as previously described (22) . '25I-Insulin, '25I-IGF-I, and 25I-MSA were prepared by the stoichiometric chloramine T procedure as previously described (4, 13). (23, 24) . Rabbit serum (A410) containing antiinsulin receptor antibody that had been raised by immunization of rabbits with purified insulin receptor of rat liver (25) was kindly provided by Dr. Steven J. Jacobs (Wellcome Research Laboratories, Research Triangle Park, NC).
Isolation of IgG
IgG fractions from control and patients' sera were isolated with protein A-Sepharose by a modification of the method of Ey et al. (26) . 1 ml of each serum was applied to a column containing 1 g protein A-Sepharose CL-4B (gel vol of 2 ml) equilibrated with borate-buffered saline (BBS), pH 8.5 (50 mM boric acid, 120 mM NaCl, 0.02% sodium azide). The flow-through was reapplied to the column. Then, the column was washed with 20 10 ,g/ml; insulin, 20 ;g/ml).
Binding, cross-linking, gel electrophoresis, and autoradiography. The crude membrane pellet was suspended in assay buffer (100 mM Hepes, 120 mnM NaCI, 1.2 mM MgSO4, 2.5 mM KCI, 1 mM EDTA, 10 mM glucose, 1.5 mM sodium acetate, pH 7.8) containing 10 mg/ml BSA at a membrane protein concentration of 1 mg/ml. The membranes (0.4 mg) were then incubated for 18 h at 4°C with 0.5-1.5 nM 1251I insulin or 2.5 nM '251-IGF-I in the absence and the presence of the indicated concentrations of unlabeled hormones or IgG. The incubation mixture was cooled to 4°C, diluted threefold with assay buffer without BSA (pH 7.4), and centrifuged at 4°C (5 min, 10,000 g). The membrane pellet was resuspended in ice-cold assay buffer without BSA to a membrane protein concentration of 1 mg/ml.
Cross-linking was performed as previously described (13) . DSS, freshly dissolved in dimethyl sulfoxide, was added to a final concentration of 0.03 mM. After 15 min, the reaction was quenched by addition of 5 vol ice-cold 10 mM Tris-HCl, 1 mM EDTA, pH 7.4, and the mixture was centrifuged (5 min, 10,000 g). The membrane pellet then was boiled for 2 min in 10 mM sodium phosphate buffer, pH 7.0, containing 2% SDS and 100 mM dithiothreitol (DTT), and the samples analyzed in 0.1% SDS-7.5% polyacrylamide gels using a discontinuous buffer system (29) . The gels were stained with 0.25% Coomassie Blue in 50% trichloroacetic acid, destained in 7% acetic acid, dried, and autoradiographed with Kodak X-Omat film (Eastman Kodak Co., Rochester, NY) using a DuPont Cronex Lightening Plus enhancing screen (DuPont Instruments, Wilmington, DE). The molecular weights of the standards are as follows: filamin, 250,000; myosin, 200,000; fB-galactosidase, 116,000; phosphorylase b, 94,000; BSA, 68,000; and ovalbumin, 43,000.
HUMAN IM-9 LYMPHOBLASTS
IM-9 cells in late log phase were sedimented and resuspended at a concentration of 5 X 107/ml in buffer (100 mM Hepes, 118 mM NaCl, 1.2 mM MgSO4, 5 mM KCI, 8.8 mM dextrose, and 10 mg/ml BSA, pH 8.0). Cells (2.5-5 X 10' in 0.1 ml) were preincubated with control or patients' IgG (0.1 ml in BBS) for 2 h at 37°C (for IGF-I binding studies) or 22°C (for insulin binding studies). After preincubation, cells were sedimented and washed three times with 2 ml phosphate-buffered saline (PBS) at 22°C. Washed, resuspended cells (2.5 X 106) were incubated with '251-insulin (40 pg) or`2I-IGF-I (250 pg) in 0.5 ml assay buffer for 2 h at 15°C. At the end of the incubation, duplicate 200-,ul aliquots were layered onto 150 gl ice-cold buffer in plastic microtubes and centrifuged at 10,000 g for 1 min in a Beckman microfuge (Beckman Instruments, Inc., Palo Alto, CA). Cell-associated radioactivity was determined by gamma counting. Nonspecific binding was determined as described for placental membranes.
BRL 3A2 CELLS Binding of`'5I-IGF-I and 1251-MSA to confluent BRL 3A2 cell monolayers was performed as previously described (7) . Incubations were at pH 7.0 in the Hepes binding buffer used with IM-9 lymphoblasts. Cross-linking and electrophoresis were performed as described above.
Immunoprecipitation of cross-linked ligandreceptor complexes 125I-IGF-I, 1251-insulin, or 125I-MSA were bound and crosslinked to human placental membranes or BRL 3A2 cells as described above. The membranes or cells were then solubilized in 25 mM Hepes buffer containing 1% Triton X-100, aprotinin (1 trypsin inhibitor unit/ml), and phenylmethylsulfonyl fluoride (PMSF) (2 mM) for 30 [vol/voll solution) (100-200 ul) was added and, after a further incubation for 1 h at 4°C, the mixture was centrifuged and washed three times with 25 mM Hepes buffer containing 0.1% Triton. The radioactivity in the pellets was counted in a gamma counter. Alternatively, the pellets were dissolved in 10 mM sodium phosphate buffer containing 2% SDS and 100 mM DTT and subjected to electrophoresis and autoradiography as described above.
Surface labeling of hepatoma cell line (Fao) Confluent Fao cells (five 100-mm dishes, 2-4 X 107 cells/ dish) were washed three times with Dulbecco's PBS and surface iodinated as previously described (30) . The reaction was carried out in 3 ml PBS/dish, which contained 20 mM glucose, 1 mCi of Na 1251I, 2 mg lactoperoxidase, and was initiated by adding glucose oxidase (200 mU/ml). After 30 min at room temperature, the cells were washed three times with cold PBS and solubilized for 30 min at room temperature in 25 mM Hepes buffer containing 1% Triton X-100, PMSF (2 mM), and aprotinin (1 trypsin inhibitor unit/ml). Insoluble material was removed by centrifugation at 100,000 g for 60 min at 4°C. The supernatant was immunoprecipitated as described above.
RESULTS
Subunit structure of insulin receptors and IGF-I receptors in human placental membranes. Human placental membranes possess specific receptors for insulin and for IGF-I (Table I ). The two receptors can be distinguished in competitive binding studies by preferential inhibition of labeled ligand binding by the homologous unlabeled ligand (31) . Both receptors also interact with the heterologous ligand at high concentrations.
The nature of the receptor proteins that bind 1251_ insulin and 1251-IGF-I was examined by covalently coupling bound radioligand with the bifunctional reagent DSS and by examining the solubilized receptor complexes by SDS-polyacrylamide gel electrophoresis and autoradiography. When examined under reducing conditions, both 125I-insulin ( Fig. 1) (Fig. 1) . The M, _ 130,000 125I-IGF-I complex was identified as a component of the IGF-I receptor by virtue of inhibition of its formation by low concentrations of unlabeled IGF-I and considerably higher concentrations of unlabeled insulin (Fig. 2) . In the absence of disulfide reduction, both the 1251-insulin and 1251-IGF-I labeled complexes had Mr > 300,000, suggesting that the Mr 130,000 binding subunits were disulfide linked to other membrane proteins (not shown). Similar results have been reported by other investigators using other IGF-I-like polypeptides (basic somatomedin [14] and somatomedin C [15] ) as radioligands and either affinity cross-linking [15] or photoaffinity labeling [14] .
Inhibition of 125I-insulin and 125I-IGF-I binding to human placental membrane and BRL 3A2 rat liver cell receptors by antiinsulin receptor antibody from patient B-2. Patients with extreme insulin resistance and acanthosis nigricans (Type B) possess circulating autoantibodies directed against insulin receptors (17) . Patient B-2 has one of the highest titers of these antibodies, and hence her serum and IgG have been used extensively in studies of the insulin receptor (11) . In addition, we previously have shown that Fab fragments prepared from IgG B-2 inhibited '251-IGF-I binding to cultured human fibroblasts (32) .
The ability of IgG B-2 to inhibit '251-insulin and 1251_ IGF-I binding to placental membranes is compared in Fig. 3 . Radioligand was incubated with membranes in the presence of 0, 10, and 100 ,ug/ml of IgG B-2. Bound radioactivity was cross-linked with DSS and examined by SDS-polyacrylamide gel electrophoresis under reducing conditions. IgG B-2 inhibited the for- r-_ FIGURE 1 Autoradiogram showing the specificity of 1251_ insulin receptor complexes cross-linked to human placental membranes and examined under reducing conditions. Human placental membranes (400 Ag) were incubated with 125j_ insulin (1 nM) (Fig. 3) , despite the fact that BRL 3A2 and placental IGF-I receptors exhibit similar reactivity with IGF-I, IGF-II, and insulin (4, 31) . This suggests that IgG B-2 may react specifically with human IGF-I receptors.
Inhibition of 1251-insulin and 125I-IGF-I binding to human placental membranes and human IM-9 lymphoblasts by IgG from patients B-5, B-6, B-8, and B-9. IgG from four other type B patients were examined for their ability to inhibit '25I-insulin and 1251-IGF-I binding to human placental membranes (Fig. 4) . Membranes were preincubated with the indicated concentrations of IgG for 5 h at 37°C. IgG from patients B-5, B-8, B-9, and B-6 (in order of potency) gave dosedependent inhibition of '25I-insulin binding, whereas control IgG was without effect (right panel). Under the assay conditions used, maximal inhibition was -60%.
Preincubation of placental membranes with two of these IgG preparations, B-5 and B-8, also resulted in an inhibition of '25I-IGF-I binding with a similar concentration dependence (left panel), although maximal inhibition of 125I-IGF-I binding was only -30%. By contrast, IgG from patients B-9 and B-6 were considerably less effective as inhibitors of 1251-IGF-I binding than '251-insulin binding. Based on the relative concentrations of IgG required to inhibit '25I-insulin and '25I-IGF-I binding by 50%, we estimate that IgG B-9 and B-6 were eight-to 10-fold less effective as inhibitors of IGF-I binding than insulin binding (Table II) .
Similar experiments were performed in human IM-9 lymphoblasts and yielded similar results (Fig. 5) . 1251_ Insulin binding was inhibited >90% by IgG B-2, B-5, and B-8, and less completely by IgG B-9 and B-6, in order of potency. IgG B-2, B-5, and B-8 also inhibited '25I-IGF-I most effectively, producing 70-90% inhibition at 300,ug/ml. As in placental membranes, IgG B-9 and B-6 were less effective inhibitors of 1251-IGF-I binding to lymphoblasts, producing 30 and 0% inhibition, respectively, at 300 ,g/ml.
These results indicate a striking parallelism of inhibitory potencies of IgG B-2, B-5, B-8, B-9, and B-6 toward insulin receptors and IGF-I receptors in both placenta and lymphoblasts. IgG B-9 and B-6 appear Immunoprecipitation of '25I-insulin and 125I-IGF receptor complexes in human placenta and BRL 3A2 rat liver cells by antiinsulin receptor antibody from patient B-2. We next compared the ability of antiinsulin receptor antibody B-2 to immunoprecipitate solubilized placental insulin and IGF-I receptor complexes. 125I-Insulin and '25I-IGF-I were affinity crosslinked to placental membranes with DSS, the receptor solubilized and immunoprecipitated with serum from patient B-2 or control serum, and analyzed by SDSpolyacrylamide gel electrophoresis under reducing conditions. As seen in the autoradiogram in Fig. 6 (left panel), serum B-2, but not control serum, immunoprecipitated both the '251-insulin receptor complexes and 1251-IGF-I receptor complexes.
Interestingly, serum B-2 also immunoprecipitated '"I-IGF-I receptor complexes from affinity cross-linked, solubilized BRL 3A2 rat liver cells (Fig. 6, right panel) . Since serum B-2 did not inhibit 1251-IGF-I binding to this receptor (Fig. 3) (9) . (Fig. 7, lower panel) . In the first experiment, sera B-2 and B-8 immunoprecipitated 7.2 and 5.6 times more radioactivity in '25I-IGF-I receptor complexes than control serum, whereas serum B-9 was only slightly more effective than control. In the second experiment, sera B-3, B-4, B-5, B-8, and A410 immunoprecipitated 2.3-4.0 times more 125I-IGF-I receptor radioactivity than control serum, whereas serum B-6 was slightly less effective than control. These results suggest that most sera with antiinsulin receptor antibodies also possess antibodies that immunoprecipitate placental IGF-I receptors.3 Two sera, B-9 and B-6, appeared to be much less reactive with the IGF-I receptor than the insulin receptor.
To evaluate further the differences in the ability of these sera to immunoprecipitate placental insulin receptors and IGF-I receptors, immunoprecipitation was examined at a range of serum concentrations (Fig. 8) . At dilutions from 1:1,000 to 1:30, sera B-6, B-8, and B-9 exhibited dose-dependent immunoprecipitation of 1251-insulin receptor complexes; sera B-8 and B-9 were similar in potency, whereas serum B-6 was less effective (center panel). By contrast, the same concentrations of sera B-6 and B-9 did not immunoprecipitate 251I-IGF-I receptor complexes to a greater extent than control serum (left panel). To exclude any contribution of antiinsulin antibodies to the immunoprecipitation of '251-insulin cross-linked to placental insulin receptors, we examined the ability of these sera to immunoprecipitate insulin receptors of Fao hepatoma cells which had been labeled by surface iodination. As seen in Fig. 8 (right panel) , sera B-2, B-6, B-8, and B-9 immunoprecipitated the iodinated insulin receptors to similar extents as the affinity-labeled insulin receptor. Fig. 7 . In this experiment, 16 .8% of input 125I_ insulin radioactivity and 33.9% of input '25I-IGF-I radioactivity was precipitable with polyethylene glycol (PEG), presumably representing radioligand complexed to receptor. Of the PEG-precipitable radioactivity, serum B-8 at 1:30 dilution immunoprecipitated 78.5% of 12511 insulin receptor complexes (1,369 cpm) and 31.7% of 125I-IGF-I receptor complexes (804 cpm). (C) Hepatoma cells (Fao) were surface iodinated by '25I-sodium and lactoperoxidase, and solubilized by Triton X-100 as described in Methods. Insoluble material was removed by ultracentrifugation, and the supernate (450 Mtl of 10.0 ml) was incubated with sera containing antiinsulin receptor antibodies (B-2, B-6, B-8, B-9) or control serum at the indicated dilutions. The reaction mixture was immunoprecipitated by adding protein A, and the immunoprecipitates analyzed by SDS-polyacrylamide gel electrophoresis after reduction of disulfide bonds. The radioactivity in the M, -135,000 and -95,000 bands was determined by excising the bands from the gels and counting in a gamma counter. Fao 
